[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100054045":3},{"organization":4,"armGroups":7,"interventions":16,"overallOfficials":30,"centralContacts":22,"locations":22,"responsibleParty":34,"collaborators":22,"id":36,"slug":37,"hasResults":38,"nctId":39,"briefTitle":40,"officialTitle":41,"acronym":22,"eligibilityCriteria":42,"healthyVolunteers":43,"sex":44,"minAge":45,"maxAge":46,"enrollmentInfo":47,"targetDuration":22,"studyType":50,"phases":51,"briefSummary":53,"conditions":54,"keywords":22,"overallStatus":56,"whyStopped":22,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":61,"completionDateStruct":62,"leadSponsor":64,"locationsCount":22},{"fullName":5,"class":6},"Merck Sharp & Dohme LLC","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"MK-4082 + Diltiazem","EXPERIMENTAL","Participants will move sequentially through 2 periods. In Period 1, participants will receive a single oral dose of MK-4082 on Day 1. In Period 2, participants will receive a single oral dose of MK-4082 on Day 1 plus oral diltiazem for multiple days.",[13,14,15],"Drug: MK-4082","Drug: Diltiazem","Drug: Rescue medication",[17,23,26],{"type":18,"name":19,"description":20,"armGroupLabels":21,"otherNames":22},"DRUG","MK-4082","Oral administration",[9],null,{"type":18,"name":24,"description":20,"armGroupLabels":25,"otherNames":22},"Diltiazem",[9],{"type":18,"name":27,"description":28,"armGroupLabels":29,"otherNames":22},"Rescue medication","All participants will receive ondansetron as a rescue medication. Ondansetron is a medication used to prevent nausea or vomiting.",[9],[31],{"name":32,"affiliation":5,"role":33},"Medical Director","STUDY_DIRECTOR",{"type":35,"investigatorFullName":22,"investigatorTitle":22,"investigatorAffiliation":22,"oldNameTitle":22,"oldOrganization":22},"SPONSOR","100054045","phase-1-a-clinical-trial-of-mk-4082-in-healthy-participants-mk-4082-005-100054045",false,"NCT07697625","A Clinical Trial of MK-4082 in Healthy Participants (MK-4082-005)","A Clinical Study to Evaluate the Plasma Pharmacokinetics of a Single Dose of MK-4082 With and Without Diltiazem Coadministration in Healthy Participants","Inclusion Criteria:\n\nThe main inclusion criteria include but are not limited to the following:\n\n* Is in good health\n* Body mass index (BMI) between 18 and 32 kg\u002Fm\\^2, inclusive\n\nExclusion Criteria:\n\nThe main exclusion criteria include but are not limited to the following:\n\n* Has a history of previous surgical treatment for obesity that may induce malabsorption, history of bowel resection \\>20 cm, any malabsorption disorder, severe gastroparesis, or any GI procedure for weight loss\n* Had a recent pancreatitis or has a history of pancreatitis",true,"ALL","18 Years","55 Years",{"count":48,"type":49},18,"ESTIMATED","INTERVENTIONAL",[52],"PHASE1","Researchers are looking for new weight loss medicines for people with higher body weight. The trial medicine, MK-4082, is different from similar weight loss medicines because people take it as a pill instead of an injection. Before giving a trial medicine to participants with a health condition, researchers first do trials in healthy participants to find a safe dose level (amount) of the trial medicine.\n\nThe goal of this study is to learn what happens to MK-4082 in a person's body over time. Researchers will compare what happens to levels of MK-4082 in people's blood when it is taken without (Period 1) and with (Period 2) another medicine called diltiazem. Researchers also want to learn about the safety of MK-4082 taken with and without diltiazem and if people tolerate them.",[55],"Healthy","NOT_YET_RECRUITING","2026-07-10",{"date":59,"type":60},"2026-07-13","ACTUAL",{"date":59,"type":49},{"date":63,"type":49},"2026-09-28",{"name":5,"class":6}]